Extended Data Fig. 1: Circulating tumor DNA analysis.
From: Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
a, Heatmap of genetic alterations detected using Guardant360 CDx. b, Progression-free survival and overall survival according to the presence of genetic alterations in the Wnt/β-Catenin pathway, evaluated by circulating tumor DNA analysis. Two-sided Log-rank test was used for comparison.
